New LaunchMay 26, 2026, 04:07 PM
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer
AI Summary
Myriad Genetics announced the launch of its Prolaris + AI Test, a new prostate cancer biomarker test combining clinical-pathological features, a molecular score, and AI-powered digital pathology. This test aims to improve active surveillance planning by identifying patients safe for active surveillance and personalizing its intensity, addressing a critical gap in prostate cancer management. The AI metric will be available for U.S. Prolaris Biopsy Tests (excluding New York State) processed from May 29, 2026, with New York approval expected soon.
Key Highlights
- Myriad Genetics launched the Prolaris + AI Test for prostate cancer, combining molecular score and AI digital pathology.
- The test helps identify patients safe for active surveillance and personalize its intensity.
- Technology is built upon PATHOMIQ AI, a digital pathology AI platform company.
- An AI model was trained on 998 patients and validated in a cohort of 296 patients.
- The AI-GUR is a statistically significant predictor of Gleason upgrade at next biopsy.
- The test will be available for U.S. Prolaris Biopsy Tests (excluding NY) processed from May 29, 2026.
- Prostate cancer is projected to be the leading cancer diagnosis in the U.S. this year, with over 300,000 new diagnoses.
Price Impact
More from MYGN